Interest in peripheral markers of central cholinergic activity has recently been revived by the discovery that cholinergic neurons in the basal forebrain (substantia innominata, septum, diagonal band of Broca) are affected in patients with Alzheimer-type dementia,' as well as in patients with Parkinson's disease2 and progressive supranuclear palsy,3 diseases which are also associated with cognitive deficiencies. The degree of the neuronal disorder in both Alzheimer's and Parkinson's disease has been correlated with the severity of intellectual deterioration.2 4 Leaving aside the question of the therapeutic strategies this might suggest, hope was raised that a peripheral cholinergic marker reflecting central cholinergic activity would offer a clear criterion distinguishing degenerative dementia (Alzheimer's disease most importantly) from other tractable dementias and severe depression.
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Results obtained in studies of acetylcholinesterase (AChE) in cerebrospinal fluid (CSF) of patients with Alzheimer's disease have been highly contradictory:
increased"1 or decreased8 BChE have been reported.
In a recent study,8 neuropsychological test scores were found to correlate with BChE activity. Methodological differences might explain these discrepancies: assays of total cholinesterase activity or assays which distinguish AChE and BChE, sampling procedure (lumbar or ventricular CSF), storage of samples, choice of control population. However, the hypothesis that CSF AChE reflects cholinergic innervation of the brain or central cholinergic activity (innervation and activity are not equivalent), is itself in need of validation. It is necessary to answer to three questions. Is AChE, which is not found exclusively in cholinergic neurons,'3 a valid marker of cholinergic innervation in the brain? Does AChE in cerebrospinal fluid reflect AChE activity in the brain? Can pathology-induced changes in brain AChE activity be detected in CSF?
A tentative answer to the first question was given in a previous study,'4 where it was shown that AChE activity in the frontal cortex was significantly correlated with the activity of choline acetyltransferase (CAT), an enzyme found only in cholinergic neurons, and would seem, therefore, in spite of its lesser A cetylcholinesterase and butyrylcholinesterase activity in the cerebrospinalfluid ofpatients specificity, to be a valid marker of cholinergic innervation, at least in the cortex. To determine whether AChE activity in the cerebrospinal fluid may also be a valid marker of AChE activity in the brain, the different molecular forms of AChE and BChE were studied in the CSF of patients with a variety of degenerative diseases of the central nervous system, with and without dementia, with and without known cholinergic lesions.
Material and methods

Subjects
The subjects (tables 1 The sucrose gradient profiles of AChE and BChE in the CSF and frontal cortex of representative control subjects are shown in fig 1 . The molecular forms of both enzymes were similar in CSF and brain homogenates with respect to the forms present, their sedimentation properties, the relative proportions of the different forms of each enzyme, and the relative proportions of AChE to BChE.
In the subjects studied, total AChE and 1OS AChE, the principal form of the enzyme, were significantly correlated (r = 0-9444; p < 0001), as were total BChE and IOS BChE (r = 0-9130; p < 0-001). Ruberg, Villageois, Bonnet, Pillon, Rieger, Agid IOS AChE were also correlated (r = 05680; p < 0 001), as were 4S and IOS BChE (r = 05524; p < 0-001).
The concentrations of IOS AChE and BChE and protein in the CSF of the control and pathological subjects are shown in fig 2. The levels of IOS AChE differed little among the various groups. They were significantly higher in demented Parkinsonian patients than in all the other groups except the controls, and significantly lower in patients with Huntington's chorea than all the other groups except for multiple sclerosis, progressive supranuclear palsy and non-demented Parkinsonians. 1OS AChE in patients with multiple sclerosis was significantly lower than in controls.
Mean BChE activity paralleled that of AChE. 1OS AChE and 1OS BChE activity were significantly correlated when all subjects were grouped together (r = 04823; p < 0 001). Significant correlations were also obtained within some of the groups, in spite of the small numbers of subjects: C2 (r = 0-7338; p, < 0-02); ALZ (r = 0 5875; p < 0 05); TDA (r = 0-7877; p < 0-05). hood onst dystonia group was significantly higher (011844 + 0 0309) than that of the control groups and patients with Alzheimer's disease (p < 0 05).
The pattern of mean protein concentrations seemed to parallel that of the cholinergic enzymes in the groups of demented patients (Alzheimer's and Parkinson's diseases, progressive supranuclear palsy, Huntington's chorea), but were not correlated either within the groups or across the groups of demented patients. The mean elevated protein concentrations in certain groups of patients (Parkinson's disease, multiple sclerosis, torsion distonia) did not reflect the group as a whole but rather isolated cases, as indicated by the large standard errors of the means for these groups. One demented Parkinsonian patient and one childhood onset dystonia patient who had abnormally high CSF protein concentrations (> 1 g/ml), also had unusually elevated lOS BChE concentrations (BChE/AChE ratios > 0-3). There was, however, no consistent association between CSF protein and BChE concentrations.
There were no significant correlations with age, disease duration or drug treatment. Enzyme concentrations in demented patients were not correlated with the global deterioration score or performance on individual neuropsychological tests.
Discussion
It had previously been shown that AChE activity in frontal cortex is correlated with CAT activity, a specific marker of cholinergic innervation, indicating that it may also be a valid marker of cholinergic innervation in the brain, at least in the frontal cortex.'4 When the sucrose gradient profiles of AChE and BChE in CSF from normal subjects were compared with those obtained with brain homogenates, it was observed that the same forms of the enzymes were present, in the same proportions. Concen If CSF AChE levels do not reflect known cholinergic lesions, they reflect even less the functional consequences of these lesions, in particular dementia. In the first place, the cognitive deficiencies in patients with Parkinson's disease, Alzheimer's disease and supranuclear palsy are not due uniquely to lesions of the innominato-cortical system,' 18 and patients may become demented without this cholinergic lesion (Huntington's chorea).
It has been suggested, on the basis of studies showing increases in BChE activity in brain'9 or CSF" of patients with Alzheimer's disease that the ratio of the two enzymes would better distinguish these subjects than the individual enzymes. The present results do not confirm this hypothesis. BChE activity in the CSF was found to be correlated with AChE activity, and the ratio of the enzymes was similar in all the groups with the exception of childhood onset dystonia.
Ruberg, Villageois, Bonnet, Pillon, Rieger, Agid BChE levels are slightly elevated in some of these patients, for reasons which are unknown. Elevated levels of the enzyme were also observed in a few isolated patients in other groups as well. The reason for this is unknown, as is the function of this enzyme. It is thought to be located for the most part in glial cells,'3 but the parallel between AChE and BChE in the CSF, and the similar effects of pathological conditions on the two enzymes suggest that the synthesis and regulation of the enzymes may be closely related, but not necessarily so, since dissociation of the enzymes was observed in some cases. It is possible that only BChE released in parallel with AChE from central neurons is found in the CSF, whereas glial enzyme does not reach this compartment. However, the observation that the ratio between AChE and BChE is similar in brain tissue and CSF would not be consistent with this hypothesis.
In conclusion, although AChE may be considered a valid marker of cholinergic innervation in the brain, and AChE activity in the CSF may reflect AChE activity in the brain, pathologically induced changes in brain AChE activity are not directly reflected in the concentrations of AChE in the CSF, and will, therefore, not provide the diagnostic marker anticipated. Results obtained in previous studies of AChE in the CSF of patients with Alzheimer's disease are consistent with this conclusion.
